DHA (Docosahexaenoic Acid)
1. Identity: Chemical Names, Structure, and Natural Sources
Chemical Identity
Docosahexaenoic acid (DHA) is an omega-3 fatty acid that is an important component of the human brain, cerebral cortex, skin, and retina. It is given the fatty acid notation 22:6(n−3). Structurally, DHA is a carboxylic acid (−oic acid) with a 22-carbon chain (docosa- derives from the Ancient Greek for 22) and six (hexa-) cis double bonds (−en−), with the first double bond located at the third carbon from the omega end.
The trivial name of DHA is cervonic acid, and it is systematically named as (all-cis)-docosa-4,7,10,13,16,19-hexaenoic acid [22:6(n−3)]. The molecular formula of DHA is C22H32O2 and the molecular weight is 328.5 g/mol. Additional identifiers include CAS registry number 6217-54-5, PubChem CID 445580, and European Community (EC) Number 612-950-9.
ALA contains 18 carbon atoms, whereas EPA and DHA are considered "long-chain" (LC) omega-3s because EPA contains 20 carbons and DHA contains 22. EPA is known as C20:5n-3 and DHA as C22:6n-3.
Biosynthesis and Endogenous Production
In humans, DHA is either obtained from the diet or may be converted in small amounts from eicosapentaenoic acid (EPA, 20:5, ω-3). With the identification of FADS2 as a human Δ4-desaturase in 2015, it is now known that humans follow the same synthesis pathway as aerobic eukaryotes, involving Δ5-elongation to DPA and Δ4-desaturation to DHA. DHA is not an essential fatty acid in the strictest sense, as it can be metabolized to some extent from its dietary essential precursor α-linolenic acid (ALA). However, the route from α-linolenic acid is ineffective, converting only about 0.05% of ALA into DHA.
Aerobic eukaryotes, specifically microalgae, mosses, fungi, and some animals, perform biosynthesis of DHA as a series of desaturation and elongation reactions, catalyzed by the sequential action of desaturase and elongase enzymes. Phytoplankton, and not animals, is the main producer of docosahexaenoic acid in the biosphere; DHA and EPA, going up the food chain, reach human tables via marine animals.
Natural Dietary Sources
DHA can be synthesized from alpha-linolenic acid or obtained directly from maternal milk (breast milk), fatty fish, fish oil, or algae oil. Fatty fish are by far the richest dietary source of DHA, with each 75 g fish serving providing between 750 and 1,500 mg of EPA+DHA. Ordinary types of cooked salmon contain 500–1,500 mg DHA and 300–1,000 mg EPA per 100 grams.
Breast milk also naturally contains DHA, and its concentration increases with higher maternal intakes of EPA+DHA, while most infant formulas in the US are fortified with DHA to support brain development. Nowadays, there is also a variety of food products fortified with fish oil-derived EPA and DHA, including eggs, yogurt, milk, juice, and soy beverages.
Vegetarian diets typically contain limited amounts of DHA, and vegan diets typically contain no DHA. Fish, molluscs, and crustaceans that live in cold waters exploit the anti-freezing effect of EPA and DHA, which, due to the degree of unsaturation of the carbon chain, help to regulate the fluidity of cell membranes and act as natural antifreeze agents.
Commercial Production
There are many types of microalgae that can synthesize DHA, and Schizochytrium sp. is the most prominent microorganism for n-3 LCPUFA production by large-scale fermentation technology. DHA-rich oil from Schizochytrium sp. has been generally recognized as safe (GRAS) for food use and dietary supplement. The oil is primarily present in triglyceride (TG) form and the commercial oil contains approximately 40% DHA of total fatty acids. Although the market share of n-3 LCPUFA supplements from Schizochytrium sp. is lower than that of marine animal oil, the growth is appreciable due to its vegetarian nature, environmental friendliness, and absence of ocean pollutants. However, the fermentation and refining of algal oil currently cost more than the extraction and refining of fish oil.
Supplement Forms and Preparations
Long-chain omega-3s are present in several dietary supplement formulations, including fish oil, krill oil, cod liver oil, and vegetarian products that contain algal oil. A typical fish oil supplement provides about 1,000 mg fish oil, containing 180 mg EPA and 120 mg DHA, but doses vary widely. Cod liver oil supplements provide vitamin A and vitamin D in addition to long-chain omega-3s.
Many supplements, including fish oil, krill oil, cod liver oil, and algal oil (for vegetarians), exist on the market containing varying doses of EPA and DHA, depending on the supplement. The major molecular forms of DHA found in supplements include:
- Natural triglyceride (TG): The form predominant in conventional fish oil; the EPA and DHA delivered in fish oil and algal oil is largely in the form of triglycerides.
- Ethyl ester (EE): Most studies agree that the EE form appears to be the least bioavailable form compared to the conventional TG structure.
- Re-esterified triglyceride (rTG): Re-esterified triglyceride and phospholipid forms generally offer superior absorption compared to ethyl esters.
- Phospholipid-bound (krill oil): The lipid classes in krill oil are quite different from fish oil, with krill oil containing phospholipid, di- and tri-glycerides, as well as non-esterified fatty acid forms, while fish oil is primarily triglycerides.
- Free fatty acid (FFA): Bioavailability for isolated chemical forms has been ordered as: NEFA > PL > rTAG > unmodified TAG > ethyl esters (EE).
DHA in phospholipid and triglyceride forms is more readily absorbed by the body than in ethyl ester form. In addition, dietary lipids in meals and emulsification of DHA oil can increase the bioavailability of DHA. Recently, conflicting information has been published on the relative bioavailability of omega-3 supplements. A few studies suggested that the phospholipid form (krill) is better absorbed than the fish oil ethyl ester or triglyceride forms. Yet some studies did not match the doses administered nor the concentrations of DHA and EPA per supplement across comparisons, leading to questionable conclusions.
2. Traditional and Historical Use
DHA as an isolated compound is a product of modern biochemical analysis; it was not identified or isolated until the 20th century. No traditional medicinal system extracted, named, or prescribed DHA as a discrete substance. Nevertheless, the consumption of foods that are now known to be rich in DHA has deep historical and cultural roots.
Scientific interest in DHA and omega-3 fatty acids was spurred by epidemiological research dating back to the 1970s that found low rates of myocardial infarction and other coronary events among Greenland Inuit and other fish-eating populations, such as those in Japan. In 1972, Bang and Dyerberg compared the dietary difference and serum lipoprotein levels between Inuit and Danes. They found that Inuit were not prone to coronary heart disease, and they ate a lot of seal and whale meat and also blubber. These findings, not yet understood at the molecular level, provided the foundational impetus for the modern era of omega-3 research.
No traditional medicinal system isolated DHA as a distinct compound; populations consuming diets high in oily fish historically show associations with better cardiovascular and developmental outcomes — traditional fish consumption rather than isolated DHA was the practical antecedent. In Japanese coastal cultures, for example, diets based on salmon, tuna, sardines, mackerel, and herring constituted the traditional pattern that incidentally delivered high quantities of both EPA and DHA.
DHA is widely used as a food supplement and was first used primarily in infant formulas. In 2019, the US Food and Drug Administration published qualified health claims for DHA.
3. Key Constituents and Established Mechanisms of Action
Structural Role in Cell Membranes
A major structural component of the mammalian central nervous system, DHA is the most abundant omega-3 fatty acid in the brain and retina. High contents of DHA have been identified in the gray matter of the brain (up to 20% of its total lipids) and in the outer rod segments of the retina. DHA contributes to approximately 97% and 93% of the n-3 PUFA in these organs, respectively.
Brain and retinal function rely on dietary intake of DHA to support a broad range of cell membrane and cell signaling properties, particularly in grey matter and retinal photoreceptor cell outer segments, which are rich in membranes. As a component of neuronal membranes, the function of DHA is to support neuronal conduction and to allow the optimal functioning of neuronal membrane proteins such as receptors and enzymes.
Computerized three-dimensional energy-minimized structures of DHA demonstrated that its final double bond enables the molecule to take a slightly spiral (helical) structure. This property is thought to provide the membrane with a certain molecular order or "fluidity" that may be required for optimal functioning. Recent molecular dynamic modeling of phospholipid bilayers has consistently demonstrated increased membrane flexibility when DHA is present compared with other fatty acids.
Biosynthesis of Specialized Pro-Resolving Mediators (SPMs)
Indirect mechanisms for DHA include mediation of anti-inflammatory effects via its oxidation to potent signaling molecules, resolvins and protectins, collectively known as docosanoids. During conditions of tissue stress, both EPA and DHA may be released from phospholipids to undergo conversions to "resolution phase interaction products," known as resolvins. Two distinct resolvin molecules have been identified for EPA (E1 and E2) and four for DHA (D1–D4). Oxidation occurs via the LOX enzymes.
The term resolvins (resolution phase interaction products) was first introduced to signify that the new structures were endogenous mediators possessing very potent anti-inflammatory and immunoregulatory actions, which include reducing neutrophil traffic, cytokine and reactive oxygen species regulation, as well as lowering the magnitude of the inflammatory response in vivo.
In addition to resolvins, DHA has been discovered as the precursor for a newly identified docosanoid called protectin, or neuroprotectin when it is found in the central nervous system. DHA can also be enzymatically converted through 15-LOX action via an epoxide-containing intermediate to the protectin family (also known as neuroprotectins in neural tissues). In normal nervous tissue, the active lipid mediators of DHA — resolvins and neuroprotectins — control the duration and magnitude of inflammation partly through the inhibition of oxidative stress and apoptotic processes. NPD1 has been shown to up-regulate the antiapoptotic proteins Bcl-2 and Bcl-xL and to decrease the expression of the proapoptotic proteins Bax and Bad in neurons and human retinal pigment epithelial cells.
DHA is metabolized in neural tissues to produce bioactive mediators such as NPD1 (neuroprotectin D1), which has anti-inflammatory and antioxidant effects. Another lipid mediator synthesized from DHA, synaptamide, is anti-inflammatory and promotes neurogenesis and synaptogenesis through receptors like GPR110. This interaction activates the cAMP/PKA signaling pathway that promotes neurogenesis, neurite growth, and synaptogenesis.
Antioxidant Signaling
DHA activates the NRF2 (nuclear factor erythroid 2-related factor 2) signaling pathway, driving the production of antioxidant enzymes like superoxide dismutase (SOD) and glutathione peroxidase (GPx). These enzymes neutralize free radicals, protecting neurons from oxidative damage.
Anti-Inflammatory Mechanisms
DHA appears to exert pleiotropic mechanisms of action by forming intracellular reactive oxygen species (ROS), modulating protein expression important for cell cycle regulation, altering membrane fluidity and function of membrane-associated proteins, inhibiting eicosanoid synthesis, and mobilizing intracellular Ca2+. The anti-inflammatory role of DHA may also be mediated through activation of adiponectin secretion through the PPAR-γ pathway. Adiponectin improves lipid oxidation and reduces insulin resistance and inflammation.
Cardiovascular Mechanisms
Omega-3 fatty acids such as EPA and DHA may reduce the risk of atherosclerotic cardiovascular disease (ASCVD) events through various mechanisms, including triglyceride lowering, membrane stabilization, and antithrombotic, anti-inflammatory, or antiarrhythmic properties. EPA and DHA modulate lipid metabolism, inflammation, platelet and endothelial function, the gut-heart axis, ion channels, and autonomic function via vagal tone, supporting cardiovascular health.
Neurological Mechanisms
DHA is the major n-3 long-chain polyunsaturated fatty acid in brain gray matter, representing about 15% of all fatty acids in the human frontal cortex. DHA affects neurogenesis, neurotransmitter signaling, synaptic plasticity and transmission, and signal transduction in the brain. Data from human and animal studies suggest that adequate levels of DHA in neural membranes are required for maturation of cortical astrocytes, neurovascular coupling, and glucose uptake and metabolism. Some metabolites of DHA also protect against oxidative tissue injury and stress in the brain.
4. Scientific Evidence by Area of Use
4.1 Cardiovascular Disease and Triglyceride Reduction
Many studies have assessed the effects of omega-3s — primarily EPA and DHA — on CVD and CVD risk factors such as high blood pressure and elevated plasma lipids. This interest was spurred by epidemiological research dating back to the 1970s that found low rates of myocardial infarction and other coronary events among Greenland Inuit and other fish-eating populations, such as those in Japan.
Triglyceride lowering is one of the best-characterized and most consistent effects of DHA and EPA. At doses of 3 to 5 g/d, EPA and DHA will reduce triglyceride levels by 20% to 30%, and a dosage of 3.4 g/d has been shown to reduce levels by almost 50% in patients with severe hypertriglyceridemia (triglycerides >750 mg/dL).
Randomized controlled trial evidence on broader cardiovascular outcomes is more heterogeneous. A meta-analysis of 38 randomized controlled trials of omega-3 FAs, stratified by EPA monotherapy and EPA+DHA therapy, estimated random-effects rate ratios with 95% confidence intervals and rated the certainty of evidence using GRADE. This systematic review and meta-analysis noted moderate certainty of evidence favoring omega-3 FAs for reducing cardiovascular mortality and outcomes. The magnitude of relative reductions was more robust in EPA-only trials versus those of EPA+DHA, suggesting differential effects of EPA and DHA.
In a meta-analysis of all published evidence of clinical trials comparing EPA alone or EPA+DHA versus control (134,144 participants), omega-3 supplementation reduced the risk of myocardial infarction and cardiovascular death, to a modest extent. However, when trials administering EPA alone were separately analyzed, a further significant risk reduction was demonstrated. Importantly, these benefits were also observed in subjects already taking statins.
Two notable trials — STRENGTH and OMEMI — which used EPA+DHA combinations at high doses, had negative results, raising questions about the utility of EPA+DHA combinations in preventing atherosclerotic cardiovascular events. While individual RCTs have produced variable results, updated cohort data and recent meta-analyses consistently link higher intake or circulating levels of EPA and DHA to reduced risk of cardiovascular events.
Heart rate: When DHA and EPA were separately administered, a modest heart rate reduction was observed in trials that supplemented with DHA (−2.47 bpm; 95% CI: −3.47, −1.46 bpm), but not in trials with EPA. This meta-analysis provides strong clinical evidence demonstrating the effect of heart rate reduction by n-3 LCPUFA supplementation, specifically attributable to DHA rather than EPA.
Evidence strength summary: The evidence for DHA/EPA combined on triglyceride reduction is strong and consistent. Evidence for reduction of major cardiovascular events is mixed and heterogeneous across trials, with some indication that EPA-only formulations may outperform EPA+DHA combinations in cardiovascular event prevention. Most evidence for health benefits of n-3 LCPUFAs is based on studies of fish consumption and/or fish oil supplementation that contain both EPA and DHA in different proportions. Therefore, relatively little is known about the unique effects of DHA without the confounding effects of dietary EPA.
4.2 Atrial Fibrillation
Evidence from RCTs indicates that high-dose supplementation may be associated with an increase in atrial fibrillation (AF) risk. A meta-analysis of 34 RCTs (36 datasets; n=114,326) found that only studies including patients at high risk for CVD who were treated with high doses of EPA/DHA (>1,500 mg/day) showed a statistically significant increase in AF risk, with a pooled odds ratio of 1.48 (95% CI: 1.21–1.81) and an absolute risk difference of 0.8%. None of the other three groups (high-risk/low-dose, low-risk/low-dose, low-risk/high-dose) showed statistically significant levels of AF risk.
Evidence strength summary: There is moderate-to-strong evidence from multiple RCTs and meta-analyses that high-dose EPA/DHA supplementation (>1,500 mg/day) increases the risk of incident atrial fibrillation, particularly in patients already at elevated cardiovascular risk.
4.3 Brain Development and Infant Neurodevelopment
As a primary structural component of neural membranes, DHA plays a critical role during periods of rapid brain growth, particularly in the third trimester of pregnancy. In humans, the third-trimester placental supply of maternal DHA to the growing fetus is critically important as the growing brain obligatorily requires DHA during this window period.
Although recent systematic reviews and meta-analyses have failed to report a consistent beneficial effect of higher DHA intakes on cognitive and visual function early in life, most reported a beneficial effect on gestational length and infant birth weight. One systematic review concluded that there is "limited evidence" for a favorable effect of supplementation in pregnancy on cognitive outcomes, and "insufficient evidence" to evaluate other developmental outcomes. These findings were based on 8 randomized controlled trials and 1 prospective cohort study.
Specific trial data include: In women randomized to a daily supplement of 500 mg DHA from 20 weeks of gestation to term, newborn cord blood DHA was associated with better neurological outcomes in children at age 5.5 years. Male neonates whose mothers received a supplement providing 600 mg of DHA during pregnancy had significantly larger total and regional brain volumes. The large DHANI trial, carried out in India, evaluated prenatal and 6 months of post-partum 400 mg/day maternal DHA supplementation. The study reported that mean development quotient (DQ) scores in the DHA and placebo groups were not statistically significantly different after 12 months of maternal supplementation through pregnancy and lactation.
A meta-analysis of RCTs on routinely supplemented infant formula milk with DHA found no beneficial role in neurodevelopmental outcomes. Trials focused on neurodevelopment in children suffer from inconsistencies in doses, sources of the supplemented fatty acids, timing of supplementation, outcome measures used, and frequencies of various neonatal co-morbidities in the samples.
A systematic review of the relationship between seafood consumption during pregnancy and child neurodevelopment concluded there was "moderate and consistent evidence" that consumption of commercially available seafood during pregnancy is associated with favorable offspring neurocognitive development. This conclusion was based on a review of 29 prospective cohort studies comprising 102,944 mother-child pairs.
Evidence strength summary: The evidence for DHA as a structural requirement for fetal and infant brain development is strong at the mechanistic level. However, RCTs of DHA supplementation in pregnancy have produced mixed results on cognitive outcomes specifically; effects on gestational length and birth weight are more consistently positive. Observational evidence linking maternal seafood consumption to offspring neurodevelopment is moderate and consistent.
4.4 Cognitive Function in Adults and Aging
A low DHA level in the brain is associated with behavioral changes and has been linked to learning difficulties and dementia. As a component of neuronal membranes, DHA functions to support neuronal conduction and to allow the optimal functioning of neuronal membrane proteins such as receptors and enzymes.
The NIH Office of Dietary Supplements identifies Alzheimer's disease, dementia, and cognitive function as research areas of interest for omega-3s. Areas examined by the NIH include CVD, infant health and neurodevelopment, cancer prevention, Alzheimer's disease, dementia and cognitive function, age-related macular degeneration, dry eye disease, rheumatoid arthritis, and other conditions. Evidence from clinical trials on DHA supplementation and cognition in adults remains preliminary; most large systematic reviews in this area have produced inconclusive results, and translating animal and mechanistic findings to human clinical benefit has proven difficult.
4.5 Age-Related Macular Degeneration (AMD)
DHA levels are especially high in the retina (eye), brain, and sperm cells. Brain and retinal function rely on dietary intake of DHA to support a broad range of cell membrane and cell signaling properties, particularly in retinal photoreceptor cell outer segments, which are rich in membranes.
Observational evidence is encouraging: In the Blue Mountains Eye Study, higher intake of omega-3 fatty acids lowered risk of early AMD by 60% after 5 years; at 10 years the reduction was attenuated and not significant. In the Age-Related Eye Disease Study (AREDS), after 6.3 years of follow-up, risks for central geographic atrophy were 45% and 56% lower in those with high intake of DHA and EPA, respectively. Higher intakes of DHA and EPA were also associated with approximately 25% lower risks for progression to advanced AMD after 8 years follow-up in AREDS.
However, interventional trial data do not replicate these observational benefits as clearly. Two major NIH-sponsored studies, AREDS and AREDS2, showed that dietary supplements containing specific combinations of vitamins, antioxidants, and zinc helped slow the progression of AMD in people at high risk. AREDS2, which had more than 4,000 participants and was completed in 2013, also tested EPA and DHA. The results showed that adding these omega-3s to the supplement formulation did not provide any additional benefits.
Once someone has AMD, taking omega-3 supplements does not keep the disease from getting worse or slow down vision loss. A systematic review found that DHA had no significant benefits in improving visual field in individuals with retinitis pigmentosa.
Evidence strength summary: Observational and cohort data consistently associate high fish/DHA intake with lower AMD risk, including a dose-response relationship. However, the largest interventional RCT (AREDS2) found no additional benefit from adding EPA+DHA to the existing supplement formula. The discrepancy between observational and interventional data remains unresolved. Evidence for DHA in treating existing AMD is weak.
4.6 Rheumatoid Arthritis and Inflammatory Conditions
The anti-inflammatory mechanisms of DHA through SPM biosynthesis provide a biological rationale for its use in inflammatory diseases. Dietary supplementation with omega-3 fatty acids has been shown to decrease interleukin-1 and tumor necrosis factor production by as much as 50%. These potent anti-inflammatory actions have been applied to improve prognoses associated with various chronic inflammatory conditions, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and IgA nephropathy.
Clinical evidence in rheumatoid arthritis includes a number of trials showing reductions in joint tenderness, morning stiffness, and NSAID requirement, though results are not uniformly consistent across studies. The overall evidence from clinical trials suggests a modest symptomatic benefit of combined EPA+DHA in rheumatoid arthritis, particularly for joint tenderness and morning stiffness, but DHA-only trial data are sparse.
4.7 Dry Eye Disease
The NIH identifies dry eye disease as a research area associated with omega-3s. Areas examined by the NIH include dry eye disease and other conditions. Some clinical trials have evaluated EPA+DHA supplementation for dry eye symptom reduction, with mixed results. Large RCTs, including the DREAM (Dry Eye Assessment and Management) study, found that omega-3 supplementation was not significantly better than placebo (olive oil) for reducing dry eye symptoms.
4.8 Cancer
Evidence regarding DHA and cancer prevention is largely observational and inconsistent across cancer types. Results from observational studies using dietary intake data suggest that higher intakes of fish and/or omega-3s may reduce prostate cancer risk. Both fish and omega-3 consumption were associated with a lower risk of fatal prostate cancer in a cohort of 293,464 men participating in the NIH-AARP study. However, a number of systematic reviews and meta-analyses of prospective studies of the effects of fish intakes, omega-3 intakes, and omega-3 blood levels on prostate cancer risk have had inconsistent findings. Circulating levels of EPA, but not DHA, were positively associated with prostate cancer risk in one meta-analysis.
Evidence strength summary: Evidence on DHA and cancer is currently insufficient to draw firm conclusions. Findings are inconsistent across cancer types and between observational and interventional study designs.
5. Body Systems and Health Areas Associated with DHA
- Central Nervous System: DHA is the most abundant n-3 PUFA in the brain, whereas only a small amount of EPA has been detected. It supports neuronal membrane structure, neurotransmitter function, synaptic plasticity, and neuroprotection via SPMs.
- Visual System: DHA levels are especially high in the retina. It is a critical structural component of photoreceptor outer segment membranes.
- Cardiovascular System: DHA and EPA reduce serum triglycerides, modulate heart rate, and have antithrombotic and anti-inflammatory effects; however, evidence for protection against major cardiac events from EPA+DHA combinations is mixed.
- Immune System: Resolvin D series (RvDs), protectins, and maresins (MaRs) are DHA-derived lipid mediators that potently promote inflammation resolution by shortening neutrophil lifespan and promoting macrophage phagocytosis of apoptotic cells.
- Reproductive and Developmental Systems: DHA is concentrated in placental transfer and maternal breast milk and is critical for fetal brain and retinal development during the third trimester.
- Musculoskeletal/Inflammatory System: Via inhibition of pro-inflammatory eicosanoids and production of pro-resolving mediators, DHA has established anti-inflammatory effects relevant to conditions such as rheumatoid arthritis.
- Metabolic System: DHA contributes to lipid metabolism, modulation of PPAR-γ pathways, and adiponectin secretion, with implications for insulin sensitivity and hepatic lipid handling.
6. Dosage Forms and Dosages Reported in Studies
The 2020–2025 Dietary Guidelines for Americans and Canada's Food Guide recommend that the general population, along with pregnant and breastfeeding females, should consume at least 8 to 12 ounces (2 servings) of seafood per week providing ≥250 mg/d of EPA+DHA. Other health organizations have also provided specific recommendations for combined EPA+DHA intakes across different population groups, ranging, on average, from 250 to 500 mg/d for adults.
Specific dosages documented in clinical and regulatory contexts include:
- General adult supplementation: A typical fish oil supplement provides about 1,000 mg fish oil, containing 180 mg EPA and 120 mg DHA, but doses vary widely.
- Hypertriglyceridemia: At doses of 3 to 5 g/d, EPA and DHA will reduce triglyceride levels by 20% to 30%. The typical daily dose of prescription omega-3 fatty acid capsules is 4 g, which provides >3 g/day of EPA+DHA.
- Pregnancy: The large DHANI trial used 400 mg/day maternal DHA supplementation from the prenatal period through 6 months post-partum. Two previously reported RCTs found beneficial effects with provision of 500 and 600 mg DHA respectively during pregnancy.
- Infant formula: There is general agreement that infant formulas should be fortified with DHA at at least 0.32% of total fatty acids to provide the average content found in breast milk worldwide. Infant formulas are typically enriched with DHA (between 0.2–0.35% of total FA) for optimal brain and visual development in both preterm and full-term infants.
- DHA in atrial fibrillation research: The range of PUFA doses tested in AF studies was between 2 g to 3 g (640 mg to 960 mg of DHA), with study durations between 6 to 12 months.
- FDA upper limit guidance: The U.S. Food and Drug Administration recommends consuming no more than 3 g/day of EPA and DHA combined, including up to 2 g/day from dietary supplements. Higher doses are sometimes used to lower triglycerides, but at these doses there are concerns about bleeding problems and possible effects on immune function.
DHA supplementation is recommended for pregnant and lactating women (≥200–300 mg/day), for individuals with low dietary fish intake seeking neurodevelopmental or visual support, and as part of therapeutic regimens for hypertriglyceridemia (2–4 g/day combined EPA+DHA) under clinical supervision.
7. Safety Considerations and Notable Interactions
General Tolerability
Any side effects from taking omega-3 supplements in smaller amounts are usually mild. They include an unpleasant taste in the mouth, bad breath, heartburn, nausea, and stomach discomfort. Although seafood contains varying levels of methyl mercury (a toxic heavy metal), omega-3 supplements have not been found to contain this contaminant because it is removed during processing and purification.
Atrial Fibrillation Risk at High Doses
Meta-analytic evidence suggests that treatment with EPA/DHA is most likely to increase risk for atrial fibrillation in patients at high risk for CVD who are treated with high doses of EPA/DHA. This is a clinically significant finding, particularly for individuals prescribed high-dose omega-3 pharmaceutical products for hypertriglyceridemia.
Anticoagulant Interactions and Bleeding
Higher doses used to lower triglycerides could cause bleeding problems and possibly affect immune function. DHA has been associated with anticoagulant products in AF studies. The range of PUFA doses tested was between 2 g to 3 g (640 mg to 960 mg of DHA); this association did not report a significant side effect of bleeding. Nevertheless, standard clinical guidance advises caution when combining high-dose omega-3 supplements with anticoagulant or antiplatelet medications.
Allergic Reactions
Supplements that contain DHA may be made from fish or krill. Individuals with fish or shellfish allergies may be at risk of an allergic reaction to these supplements. Some DHA supplements are made from algae, which may be safe for people with fish or shellfish allergies.
Product Quality and Oxidation
DHA, as a highly unsaturated fatty acid, is susceptible to oxidative degradation. Oxidation degrades EPA and DHA in omega-3 supplements, reducing potency, bioavailability, and anti-inflammatory benefits while potentially increasing digestive side effects. Consumers and clinicians should be aware that oxidized fish oil products may deliver reduced biological activity.
Hormonal Influences on DHA Metabolism
Estrogens stimulate the biosynthesis of DHA, whereas testosterone stimulation induces a decrease in DHA. This may partially explain observed sex differences in circulating DHA levels.
Dietary Fat Co-Ingestion and Bioavailability
Many dietary supplements are in ethyl ester formulations from which EPA and DHA are poorly absorbed when consumed without a meal containing dietary fat. This is a practically relevant consideration: EE-form DHA supplements should ideally be taken with a fat-containing meal to optimize absorption.
Dietary Gap
Results of a global survey indicated that only 24% of the world adult population met the n-3 fat level set in the 2010 US guidelines from the consumption of seafood alone, while 67% had intake of less than 100 mg n-3 fats/day, especially in China, which was less than 50 mg n-3 fats/day. This global intake gap has driven significant growth in DHA supplement markets.
References
Go back